Everolimus as First-Line Therapy in Treating Patients With Prostate Cancer
Status:
Completed
Trial end date:
2019-08-08
Target enrollment:
Participant gender:
Summary
RATIONALE: Everolimus may stop the growth of tumor cells by blocking some of the enzymes
needed for cell growth and by blocking blood flow to the tumor.
PURPOSE: This phase II trial is studying the side effects of everolimus and to see how well
it works as first-line therapy in treating patients with prostate cancer.